Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effectiveness and Costs of Enhanced Cocaine Treatments

This study has been completed.
Sponsor:
Information provided by:
University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT00167258
First received: September 9, 2005
Last updated: December 14, 2009
Last verified: December 2009
  Purpose

The study will evaluate the effectiveness, economic benefits, and costs of voucher reinforcement for cocaine and alcohol abstinence, additional counseling services, and their combination in a sample of cocaine dependent patients receiving outpatient treatment as usual in a community clinic.


Condition Intervention Phase
Cocaine Dependence
Behavioral: Voucher Reinforcement
Behavioral: Extra Counseling Services
Behavioral: Voucher Reinforcement + Extra Counseling Services
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Open Label
Primary Purpose: Treatment

Further study details as provided by University of Pennsylvania:

Estimated Study Completion Date: February 2007
  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Enrollment in an intensive outpatient program (IOP) for no more than 1 month
  • Current DSM-IV diagnosis of cocaine dependence (month prior to IOP treatment)
  • 18-65 years of age
  • Ability to provide names of informants to help locate subject for follow-up

Exclusion Criteria:

  • IV heroin use in last year
  • Acute medical/psychiatric diagnosis that precludes outpatient treatment
  • Inpatient treatment for 6 weeks or more prior to IOP treatment
  • Incarceration for 6 months or more prior to IOP treatment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00167258

Locations
United States, Pennsylvania
University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
University of Pennsylvania
Investigators
Principal Investigator: James R McKay, PhD University of Pennsylvania
  More Information

No publications provided

Responsible Party: Dr. James McKay, University of Pennsylvania
ClinicalTrials.gov Identifier: NCT00167258     History of Changes
Other Study ID Numbers: 702110
Study First Received: September 9, 2005
Last Updated: December 14, 2009
Health Authority: United States: Institutional Review Board
University of Pennsylvania: IRB
City of Philadelphia: IRB

ClinicalTrials.gov processed this record on November 25, 2014